3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Breast Neoplasms
18
Triple Negative Breast Neoplasms
16
Carcinoma, Transitional Cell
4
Neoplasm Metastasis
3
Carcinoma, Non-Small-Cell Lung
3
Salivary Gland Neoplasms
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Locally Advanced Non-resectable Breast Cancer
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Metastatic Urothelial Cancer
1
Meningeal Carcinomatosis
1
Lung Diseases
1
Localized Muscle Invasive Bladder Urothelial Carcinoma
1
Liver Failure
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
Magnetic Resonance Spectroscopy
4
Surgical Procedures, Operative
3
Iodine-131
3
Iodine-124
3
Biopsy
3
selpercatinib
2
lenvatinib
2
Watchful Waiting
2
Thyrotropin Alfa
2
Therapeutics
2
Nivolumab
2
Fluorodeoxyglucose F18
2
Cyclophosphamide
2
Cetuximab
2
Biopsy, Fine-Needle
2
trastuzumab deruxtecan
1
trametinib
1
sintilimab
1
sacituzumab govitecan
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
gallium Ga 68 dotatate
1
fludarabine phosphate
1
defactinib
1
dabrafenib
1
cemiplimab
1
brodalumab
1
binimetinib
1
anlotinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Thyroid Neoplasms
×
sacituzumab govitecan
×
Clear all
NCT06923826
2025-07-25
TROP2
National University Hospital, Singapore
Phase 2
Recruiting
32 enrolled